RTT

HKBU and CUHK launch Spermine Risk Score for prostate cancer diagnosis

Retrieved on: 
Monday, February 8, 2021
Medicine, Clinical medicine, Medical specialties, RTT, Histopathology, Prostate cancer, Prostate, Cancer, Prostate-specific antigen, Active surveillance of prostate cancer

They found that prostate cancer patients in general have lower levels of spermine, a biogenic molecule in their urine, which offers a clue for the diagnosis of prostate cancer.

Key Points: 
  • They found that prostate cancer patients in general have lower levels of spermine, a biogenic molecule in their urine, which offers a clue for the diagnosis of prostate cancer.
  • The research team then used the urine spermine level figures and three other clinical parameters, namely DRE, PSA level and prostate volume, to develop the Spermine Risk Score, with the objective of offering a more accurate estimation of patients' prostate cancer risk.
  • The higher the Spermine Risk Score, the greater the patient's risk of developing prostate cancer.
  • Moreover, the negative predictive value of the Spermine Risk Score for significant prostate cancer is 95%, which means the chance of no significant cancer is 95% if the valueof the Score is negative.

HKBU and CUHK launch Spermine Risk Score for prostate cancer diagnosis

Retrieved on: 
Monday, February 8, 2021
Medicine, Clinical medicine, Medical specialties, RTT, Histopathology, Prostate cancer, Prostate, Cancer, Prostate-specific antigen, Active surveillance of prostate cancer

They found that prostate cancer patients in general have lower levels of spermine, a biogenic molecule in their urine, which offers a clue for the diagnosis of prostate cancer.

Key Points: 
  • They found that prostate cancer patients in general have lower levels of spermine, a biogenic molecule in their urine, which offers a clue for the diagnosis of prostate cancer.
  • The research team then used the urine spermine level figures and three other clinical parameters, namely DRE, PSA level and prostate volume, to develop the Spermine Risk Score, with the objective of offering a more accurate estimation of patients' prostate cancer risk.
  • The higher the Spermine Risk Score, the greater the patient's risk of developing prostate cancer.
  • Moreover, the negative predictive value of the Spermine Risk Score for significant prostate cancer is 95%, which means the chance of no significant cancer is 95% if the valueof the Score is negative.

Catapult Therapeutics receives FDA Clearance of Investigational New Drug (IND) Application for CAP-100, an innovative first-in-class humanized anti-CCR7 antibody

Retrieved on: 
Monday, February 8, 2021
Chronic lymphocytic leukemia, RTT, CLL, Cancer, Clinical medicine, Monoclonal antibodies, Drugs, Breakthrough therapy, Duvelisib

Catapult Therapeutics is now poised to initiate a Phase 1 clinical trial in patients with relapsed or refractory CLL (chronic lymphocytic leukemia).

Key Points: 
  • Catapult Therapeutics is now poised to initiate a Phase 1 clinical trial in patients with relapsed or refractory CLL (chronic lymphocytic leukemia).
  • The study will be performed at Dana-Farber Cancer Institute in Boston, where startup activities are currently underway, and two other leading clinical sites in the USA.
  • "The FDA clearance of the IND for CAP-100 represents another important milestone for Catapult Therapeutics, and we look forward to initiating the clinical trial shortly," saidWim Mol, PhD, Chief Executive Officer ofCatapult Therapeutics.
  • Catapult Therapeutics is a privately held Dutch company established in 2015 as a joint venture between Spanish and Dutch venture capital investors.

Meijer Prepares to Administer Up to 25,000 COVID-19 Vaccines to Seniors Throughout the State of Michigan This Week

Retrieved on: 
Monday, February 8, 2021
Regions of the United States, Economy of Kentucky, Meijer, Vaccine, Midwestern United States, Vaccines, Economy of the United States, RTT

The vaccines will be administered to Michiganders 65 years and older who have pre-registered through the company's vaccine registration process .

Key Points: 
  • The vaccines will be administered to Michiganders 65 years and older who have pre-registered through the company's vaccine registration process .
  • "We are very proud of the role our stores and pharmacies continue to play in this massive effort to vaccinate people against COVID-19," Meijer President & CEO Rick Keyes said.
  • "As a pharmacy partner to both the State of Michigan and the federal government, we have been able to receive vaccines and quickly administer doses to thousands of people in our communities, usually within 72 hours."
  • During the last few weeks, Meijer has conducted vaccine clinics in numerous counties throughout the state, administering up to 1,200 vaccines in a single day at some stores.

New Study Examines Allergic Reactions to Sunflower Seeds

Retrieved on: 
Monday, February 8, 2021
Medical specialties, Medicine, Immunology, Immune system, Allergy, RTT, American Academy of Allergy, Asthma, and Immunology, Allergen, Wheat allergy

The retrospective case series examined 117 adult patients sensitive to sunflower seeds.

Key Points: 
  • The retrospective case series examined 117 adult patients sensitive to sunflower seeds.
  • A total of 28 patients were recognized to have a clinical allergy to sunflower seed, amounting to 24% of those included in the study.
  • Additionally, skin testing reactivity to Artemisia pollen was more frequent in those allergic to sunflower seeds (71% vs. 22%).
  • April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
    SOURCE The American Academy of Allergy, Asthma & Immunology

Global Cancer Cell Market to Surpass US$ 14,803.5 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Monday, February 8, 2021
General Health, Pharmaceutical, Health, Oncology, RTT, Cancer, Head and neck cancer, Oncology, Causes of death, Health, Medicine

According to Coherent Market Insights, the global cancer cell market is estimated to be valued at US$ 8,525.5 million in 2020 and is expected to exhibit a CAGR of 8.20 % during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global cancer cell market is estimated to be valued at US$ 8,525.5 million in 2020 and is expected to exhibit a CAGR of 8.20 % during the forecast period (2020-2027).
  • Key companies focusing on inorganic strategies such as collaborations to develop treatment for various cancers such lung, head, and neck cancer are expected to propel growth of the global cancer cell market during the forecast period.
  • Among regions, North America is expected to hold dominant position in the global cancer cell market during the forecast period, owing to research institutes and academic institutes focusing on research and development for the treatment of cancer.
  • The global cancer cell market is expected to exhibit a CAGR of 8.20 % during the forecast period, as key companies are focusing on research and development for the treatment of cancer such as lung cancer, breast cancers and others.

BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform

Retrieved on: 
Monday, February 8, 2021
RTT, Breast cancer, Cancer, Medicine, Clinical medicine, Health, Biomarkers

This could be used as a simple and effective test to assess response to treatment and to better tailor treatment of the patient as well as reducing side-effects and costs."

Key Points: 
  • This could be used as a simple and effective test to assess response to treatment and to better tailor treatment of the patient as well as reducing side-effects and costs."
  • BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.
  • We at BioMark aspire to provide leading edge early diagnostic and monitoring of response to treatment that enables better cancer care management.
  • The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

US Esophageal Cancer Market and Competitive Landscape 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Pharmaceutical, Health, Oncology, RTT, Esophageal, Epidemiology of cancer

The "US Esophageal Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Esophageal Cancer Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Esophageal Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Esophageal Cancer pipeline products, Esophageal Cancer epidemiology, Esophageal Cancer market valuations and forecast, Esophageal Cancer drugs sales and competitive landscape in the US.
  • Esophageal Cancer pipeline: Find out the products in clinical trials for the treatment of Esophageal Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Esophageal Cancer drugs: Identify key products marketed and prescribed for Esophageal Cancer in the US, including trade name, molecule name, and company
    Esophageal Cancer market valuations: Find out the market size for Esophageal Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Esophageal Cancer drugs market share: Find out the market shares for key Esophageal Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Esophageal Cancer products

United States Fibromyalgia Market Report 2021: Epidemiology, Valuations And Forecast, Drugs Sales and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Health, Pharmaceutical, RTT, Business, Articles, Fibromyalgia, Rheumatology, Economy, Market share, Market analysis

The "US Fibromyalgia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Fibromyalgia Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Fibromyalgia Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Fibromyalgia pipeline products, Fibromyalgia epidemiology, Fibromyalgia market valuations and forecast, Fibromyalgia drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Fibromyalgia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2017 and forecast to 2026
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Fibromyalgia products

United States Rheumatoid Arthritis Market Valuations, Epidemiology, Drugs Sales and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Rheumatology, Health, RTT, Arthritis, Autoimmune diseases, Connective tissue diseases, Rheumatoid arthritis, Psoriatic arthritis

The "US Rheumatoid Arthritis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Rheumatoid Arthritis Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Rheumatoid Arthritis Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Rheumatoid Arthritis pipeline products, Rheumatoid Arthritis epidemiology, Rheumatoid Arthritis market valuations and forecast, Rheumatoid Arthritis drugs sales and competitive landscape in the US.
  • Rheumatoid Arthritis pipeline: Find out the products in clinical trials for the treatment of Rheumatoid Arthritis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Rheumatoid Arthritis drugs: Identify key products marketed and prescribed for Rheumatoid Arthritis in the US, including trade name, molecule name, and company
    Rheumatoid Arthritis market valuations: Find out the market size for Rheumatoid Arthritis drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Rheumatoid Arthritis drugs market share: Find out the market shares for key Rheumatoid Arthritis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Rheumatoid Arthritis products